Project description
Restoring immune system response in cancer patients
Recent advances in cancer immunotherapy after introduction of immune checkpoint inhibitors demonstrated great potential by achieving previously impossible 5-year survival rates for patients with metastatic cancers. However, a great number of patients worldwide remain unresponsive to immunotherapy and often do not have any other therapeutic options. French biotech start-up Stimunity aims to address this problem through the development of new drugs that activate the stimulator of interferon genes pathway to restore the innate immune system of these unresponsive patients and induce a potent and durable antitumour immune response. The company strategy is based on a safe virus-like particle technology that allows to encapsulate the best-known natural activators and efficiently deliver them into immune cells. The EU-funded STI-001 project will allow Stimunity to confirm the feasibility of the technological approach, assess regulatory issues, and validate the marketing and business plans.
Fields of science
Programme(s)
Funding Scheme
SME-1 - SME instrument phase 1
Coordinator
75008 Paris
France
See on map